Trial Profile
Multicenter clinical trials to determine the efficacy and safety of consolidation and maintenance therapy with ixazomib, lenalidomide, dexamethasone (IRd) therapy in transplant-ineligible multiple myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 May 2022
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 25 May 2022 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2018 New trial record